Skip to main content

Table 1 Comparison of baseline characteristics and laboratory test results between the patient groups treated with either nafcillin or glycopeptides

From: Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study

Characteristics

All patients

(n = 188)

Nafcillin group

(n = 91)

Glycopeptide group

(n = 97)

P value

Age, years, mean ± SD

62.37 ± 15.14

64.38 ± 14.53

60.46 ± 15.54

0.076 a

Male, (%)

129 (69.0)

61 (67.0)

68 (70.8)

0.636 b

Underlying comorbidities, yes (%)

 Cardiovascular disease

55 (29.3)

29 (31.9)

26 (26.8)

0.522 b

 Cerebral vascular accident

19 (10.1)

12 (13.2)

7 (7.2)

0.227 b

 Dementia

5 (2.7)

1 (1.1)

4 (4.1)

0.370 c

 Lung disease

14 (7.4)

8 (8.8)

6 (6.2)

0.584 b

 Autoimmune disease

10 (5.3)

4 (4.4)

6 (6.2)

0.749 c

 Peptic ulcer disease

10 (5.3)

6 (6.6)

4 (4.1)

0.527 c

 Chronic kidney disease

39 (20.7)

23 (25.3)

16 (16.5)

0.153 b

 Diabetes

62 (33.0)

35 (38.5)

27 (27.8)

0.162 b

 Liver disease

23 (12.2)

8 (8.8)

15 (15.5)

0.187 b

 Malignancy

85 (45.2)

26 (28.6)

59 (60.8)

<0.001 b

 CA vs. HCA, HCA (%)

113 (60.1)

43 (47.3)

70 (72.2)

<0.001 b

 Pit bacteremia score, mean ± SD

1.56 ± 2.55

1.42 ± 2.39

1.69 ± 2.71

0.465 a

Infection focus, yes (%)

 Catheter-related infection

22 (11.8)

12 (13.3)

10 (10.4)

0.651 b

 Pneumonia

8 (4.3)

1 (1.1)

7 (7.3)

0.066 c

 Urinary tract infection

7 (3.8)

9 (6.7)

1 (1.0)

0.058 c

 Skin and Soft tissue infection

43 (23.1)

27 (30.0)

16 (16.7)

0.037 b

 Bone and Joint infection

22 (11.8)

16 (17.8)

6 (6.3)

0.022 b

 Intra-abdominal infection

13 (7.0)

3 (3.3)

10 (10.4)

0.083 c

 Primary bacteremia

74 (39.8)

27 (30.0)

47 (49.0)

0.011 b

Laboratory tests

 WBC, /mm3, median (IQR)

10,150 (7,635–14,770)

10,450 (8,120–15,280)

9,860 (5,485–14,615)

0.064 d

 Leukocytosis or Leukopenia, yes (%)

116 (61.7)

50 (54.9)

66 (68.0)

0.073 b

 Platelet counts, ×103/mm3, median (IQR)

169 (95–250)

182 (115–257)

164 (83–250)

0.190 d

 Thrombocytopenia, yes (%)

82 (43.6)

36 (39.6)

46 (47.4)

0.305 b

 eGFR, mL/min/mm3, mean ± SD

62.88 ± 28.60

62.38 ± 28.27

63.35 ± 29.06

0.818 a

 Total bilirubin, mg/dL, median (IQR)

0.8 (0.5–1.4)

0.8 (0.5–1.3)

0.8 (0.5–1.4)

0.452 d

 Prothrombin time (INR), median (IQR)

1.12 (1.01–1.29)

1.13 (1.02–1.28)

1.11 (1.01–1.32)

0.895 d

 CRP, mg/dL, median (IQR)

121.01 (56.34–200.85)

139.60 (79.68–219.00)

107.61 (42.19–192.90)

0.022 d

  1. Abbreviations: SD standard deviation, CA community-acquired, HCA healthcare-associated, WBC white blood cell, IQR interquartile range, eGFR estimated glomerular filtration rate, INR international normalized ratio, CRP C-reactive protein
  2. aStudent’s t-test
  3. bPearson’s χ-test
  4. cFisher’s exact test
  5. dMann-Whitney U-test, median (interquartile range)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us